Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00510003
Status:
COMPLETED
Last Update Posted:
2016-11-18
First Post:
2007-07-31
Brief Title:
Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD in Patients 2- to 11- Year-old
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Multicenter 3-week Randomized Double-blind Parallel-group Vehicle-controlled Study to Evaluate the Efficacy and Safety of Pimecrolimus Cream 1 in Pediatric Patients With Mild to Moderate Atopic Dermatitis
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the efficacy and safety of pimecrolimus cream 1 in relation to the improvement of pruritus in pediatric patients 2- to 11- year-old with mild to moderate atopic dermatitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None